Febit now offers whole-genome sequencing services
Febit
Whole-genome sequencing services
Febit has announced that it now offers whole-genome sequencing services in Europe for a range of species.
The company has acquired two Applied Biosystems Solid high-throughput sequencing systems from Life Technologies that are necessary for whole-genome resequencing.
One of the two systems will be used within research and development, while the other is employed within Febit's Genomic Service Department.
Life Technologies is a biotechnology tools company providing systems, consumables and services for scientific researchers around the world.
According to Peer Staehler, chief scientific officer of Febit, the company will now be able to offer whole-genome sequencing at competitive prices; the price for resequencing a whole human genome will start at EUR9,750 (GBP8,774).
The ultra-deep resequencing with 99.94 per cent accuracy enables SNP and mutation detection as well as the detection of structural variations such as insertions, deletions, inversions and translocations, added Staehler.
The whole-genome resequencing service extends Febit's service portfolio, which includes the targeted resequencing of genomic regions of interest with its high-throughput Hybselect technology.
Together with a barcoding option, the company's new service portfolio is intended to advance the use of next-generation sequencing for larger-scale clinical studies.
More stories
Febit analyses miRNA patterns in blood samples
Study results that illustrate the high potential of microRNAs (miRNAs) as biomarkers for a range of diseases will be presented during the 42nd European Human Genetics Conference in Sweden.
Febit minimal genome technology receives EU patent
Febit has announced the receipt of an EU patent, EP 1 728 860B1, for its technology to synthesise minimal genomes.
Febit Geniom Biochip has 58 additional sequences
Febit has announced that an updated version of the company's miRBase 14 Geniom Biochip with 58 additional new sequences is now available for cancer research.
Children's hospital chooses Hybselect technology
The Children's Hospital Boston has selected Febit's Hybselect technology to enable genetics researchers to conduct the highly economic targeted enrichment of genes of interest for resequencing.
Febit - latest company news
3 December 2009 - Febit's Hybselect has been recognised as one of the winners of the Top 10 Innovations of 2009 by The Scientist magazine.


